No headlines found.
Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter
Globe Newswire (Tue, 8-Apr 8:00 AM ET)
Globe Newswire (Tue, 4-Mar 8:00 AM ET)
Globe Newswire (Tue, 4-Feb 9:25 AM ET)
Globe Newswire (Mon, 3-Feb 8:00 AM ET)
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial
Globe Newswire (Thu, 30-Jan 8:00 AM ET)
Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL Trials
Globe Newswire (Mon, 13-Jan 8:00 AM ET)
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
Jupiter Neurosciences trades on the NASDAQ stock market under the symbol JUNS.
As of April 9, 2025, JUNS stock price declined to $0.54 with 77,643 million shares trading.
JUNS has a beta of -3.22, meaning it tends to be less sensitive to market movements. JUNS has a correlation of 0.06 to the broad based SPY ETF.
JUNS has a market cap of $17.88 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that JUNS belongs to (by Net Assets): IWC.
JUNS support price is $.53 and resistance is $.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JUNS shares will trade within this expected range on the day.